Caxton Associates LP Corcept Therapeutics Inc Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$12.46 - $19.98 $663,146 - $1.06 Million	-53,222 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$11.0 - $18.26 $331,122 - $549,662	30,102 Added 130.2%	53,222 $895,000
Q1 2020 May 15, 2020	BUY	$10.11 - $14.04 $14,629 - $20,315	1,447 Added 6.68%	23,120 $275,000
Q4 2019 Feb 14, 2020	BUY	$12.06 - $16.96 $261,376 - $367,574	21,673 New	21,673 $262,000
Q4 2017 Feb 14, 2018	SELL	$15.77 - $20.72 $162,431 - $213,416	-10,300 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $126,690 - $198,790	10,300	10,300 $199,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.3B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.